Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience
NCCN Annual Conference 2019Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and lymphoma, and how clinicians are using infrastructure, navigation, and early referrals to maximize response and minimize toxicity.
Related Videos
Wells A. Messersmith, MD, on Managing Metastatic Colorectal Cancer: NCCN Guidelines Update
Wells A. Messersmith, MD, of the University of Colorado Cancer Center, discusses results of recent clinical trials, emerging treatment options, and approaches that may improv...
Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates
Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new adjuvant therapy options for patients with pancreatic cancer, and germline testi...
Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals
Gary H. Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, discusses current strategies for the use of biosimilars to treat cancer-in...
Melinda L. Telli, MD, on NCCN Guidelines Updates for HR-Positive, HER2-Negative Early-Stage Breast Cancer
Melinda L. Telli, MD, of the Stanford Cancer Institute, discusses the various systemic therapies for patients with early-stage hormone receptor–positive, HER2-negative diseas...
Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice
Chrysalyne Schmults, MD, of Brigham and Women’s Hospital, discusses treatment strategies in these nonmelanoma skin cancers, including surgery, forthcoming staging systems, an...
